GSK
NEWS
BioVersys AG announced, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.
GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.
Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.
A new method of synthesizing molecule arrangements in medicine could change the way many drugs, including the PARP inhibitor Zejula, a treatment for ovarian cancer, are produced.
The Dementia Discovery Fund this week welcomed more than 100 key stakeholders to its Annual Forum to discuss the opportunities and challenges surrounding the development of high-impact therapeutics for age-related dementias.
Companies strengthen their leadership teams and boards of directors with these appointments.
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
Nadhim Zahawi MP has announced that Stevenage Bioscience Catalyst (SBC) has been successful in its application to become a Life Science Opportunity Zone.
It was another busy week for clinical trials. Here’s a look.
JOBS
IN THE PRESS